Literature DB >> 9021208

Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea.

S Palmer1, S Cox.   

Abstract

The intracellular phosphorylation of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine was increased two- to threefold by the addition of hydroxyurea (HU) to the single drugs or to the two drugs in combination. The ratios of drug triphosphate to competing cellular deoxynucleoside triphosphate were increased two- to threefold for both 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of HU. These HU-induced increases in 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine metabolism may further enhance the anti-human immunodeficiency virus activity of these two drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021208      PMCID: PMC163730     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

Review 1.  An overview of the clinical experience with hydroxyurea.

Authors:  R C Donehower
Journal:  Semin Oncol       Date:  1992-06       Impact factor: 4.929

2.  Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

Authors:  W Y Gao; R Agbaria; J S Driscoll; H Mitsuya
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

3.  Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma.

Authors:  G J Hart; D C Orr; C R Penn; H T Figueiredo; N M Gray; R E Boehme; J M Cameron
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

4.  Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.

Authors:  W Y Gao; A Cara; R C Gallo; F Lori
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

5.  Species differences in nucleotide pool levels of 2',3'-dideoxycytidine: a possible explanation for species-specific toxicity.

Authors:  J M Lipman; J A Reichert; A Davidovich; T D Anderson
Journal:  Toxicol Appl Pharmacol       Date:  1993-11       Impact factor: 4.219

6.  Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools.

Authors:  A Meyerhans; J P Vartanian; C Hultgren; U Plikat; A Karlsson; L Wang; S Eriksson; S Wain-Hobson
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

7.  Intracellular activation and cytotoxicity of three different combinations of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  S Palmer; S Cox
Journal:  AIDS Res Hum Retroviruses       Date:  1995-10       Impact factor: 2.205

8.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

Authors:  W Y Gao; T Shirasaka; D G Johns; S Broder; H Mitsuya
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate.

Authors:  A Mazumder; D Cooney; R Agbaria; M Gupta; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

Review 10.  Nucleoside analogs: similarities and differences.

Authors:  J P Sommadossi
Journal:  Clin Infect Dis       Date:  1993-02       Impact factor: 9.079

View more
  7 in total

Review 1.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.

Authors:  J Neyts; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

3.  Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.

Authors:  S Palmer; R W Shafer; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 4.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

5.  In vitro hydroxyurea decreases Th1 cell-mediated immunity.

Authors:  A Weinberg
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

6.  The effect of hydroxyurea on the phosphorylation of zidovudine and lamivudine in human umbilical vein endothelial cells.

Authors:  Timothy R McGuire; Eric B Hoie; Konstantine K Manouilov; Peter G Gwilt
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

7.  Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.

Authors:  May Levin; Michal Stark; Bluma Berman; Yehuda G Assaraf
Journal:  Cell Death Dis       Date:  2019-05-17       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.